Search Results | Blood | American Society of Hematology

1-20 of 140

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Blood (2022) 140 (Supplement 1): 1459–1463.

DOI: https://doi.org/10.1182/blood-2022-158024

Published: 2022

Journal Articles

Indirectly Recognizable Epitopes Derived from Recipient Mismatched HLA-B Are Associated with Adverse Prognosis in Single-Unit Cord Blood Transplantation

Takeshi Sugio, Koji Kato, Naoyuki Uchida, Kohta Miyawaki, Matthias Niemann, Eric Spierings, Makoto Onizuka, Yasufumi Uehara, Masatsugu Tanaka, Noriko Doki, Tetsuya Eto, Hikaru Kobayashi, Yumiko Maruyama, Tatsuo Ichinohe, Junya Kanda, Yoshiko Atsuta, Satoko Morishima

Blood (2022) 140 (Supplement 1): 893–894.

DOI: https://doi.org/10.1182/blood-2022-164913

Published: 2022

Journal Articles

Single-Cell Transcriptome Reveals Comprehensive Immune Profiles of T Follicular Helper Cell Lymphoma

Sakurako Suma, Manabu Fujisawa, Yoshiaki Abe, Yasuhito Suehara, Daisuke Kaji, Takeshi Sugio, Koji Kato, Koichi Akashi, Kosei Matsue, Naoya Nakamura, Ayako Suzuki, Yutaka Suzuki, Shigeru Chiba, Mamiko Sakata-Yanagimoto

Blood (2022) 140 (Supplement 1): 8754–8755.

DOI: https://doi.org/10.1182/blood-2022-159804

Published: 2022

Journal Articles

YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update

Blood (2022) 140 (Supplement 1): 1056–1059.

DOI: https://doi.org/10.1182/blood-2022-162520

Published: 2022

Journal Articles

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Blood (2021) 138 (Supplement 2): LBA-6.

DOI: https://doi.org/10.1182/blood-2021-155068

Published: 2021

Journal Articles

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Blood (2021) 138 (Supplement 1): 131.

DOI: https://doi.org/10.1182/blood-2021-145025

Published: 2021

Journal Articles

CHOP Plus Sequential Mogamulizumab As First-Line Therapy for Untreated Adult T-Cell Leukemia-Lymphoma

Kazuki Tanimoto, Koji Kato, Takatoshi Aoki, Goichi Yoshimoto, Ilseung Choi, Masanori Kadowaki, Yasuhiro Sugio, Takuro Kuriyama, Noriaki Kawano, Ritsuro Suzuki, Kohta Miyawaki, Hideho Henzan, Noriyuki Saito, Takanori Ohta, Toshihiro Miyamoto, Koichi Akashi

Blood (2021) 138 (Supplement 1): 1393.

DOI: https://doi.org/10.1182/blood-2021-151937

Published: 2021

Journal Articles

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Nathan H Fowler, MD, Michael Dickinson, DMed Sci, Martin Dreyling, MD, Joaquin Martinez-Lopez, MD, Arne Kolstad, MD PhD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Monalisa Ghosh, MD, Leslie L. Popplewell, MD FACP, Julio C. Chavez, MD, Emmanuel Bachy, MD PhD, Koji Kato, MD PhD, Hideo Harigae, MD PhD, Marie José Kersten, MD PhD, Charalambos Andreadis, MD, Peter A. Riedell, MD, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), Jose Antonio Pérez-Simón, MD, Sarah J. Nagle, MD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, MD, Piers Patten, MD PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz C. Offner, MD PhD, Andreas Viardot, Professor Dr, Pier Luigi Zinzani, MD, Ram Malladi, MBBS(Lond), MRCP(UK), FRCPath, Lida Bubuteishvili Pacaud, MD, Alessandra Forcina, MD, Aiesha Zia, Stephen J. Schuster, MD, Catherine Thieblemont, MD PhD

Blood (2020) 136 (Supplement 1): 1–3.

DOI: https://doi.org/10.1182/blood-2020-138983

Published: 2020

Journal Articles

Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia

Taro Tochigi, Toshihiro Miyamoto, Kiwamu Hatakeyama, Teppei Sakoda, Daisuke Ishihara, Hidetoshi Irifune, Takahiro Shima, Koji Kato, Takahiro Maeda, Takumi Ito, Hiroshi Handa, Koichi Akashi, Yoshikane Kikushige

Blood (2020) 135 (24): 2146–2158.

DOI: https://doi.org/10.1182/blood.2019003749

Published: 2020

Includes: Supplemental data

Journal Articles

A human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells

Fumiaki Jinnouchi, Takuji Yamauchi, Ayano Yurino, Takuya Nunomura, Michitaka Nakano, Chika Iwamoto, Teppei Obara, Kohta Miyawaki, Yoshikane Kikushige, Koji Kato, Takahiro Maeda, Toshihiro Miyamoto, Eishi Baba, Koichi Akashi, Katsuto Takenaka

Blood (2020) 135 (19): 1661–1672.

DOI: https://doi.org/10.1182/blood.2019002194

Published: 2020

Includes: Supplemental data

Journal Articles

A Fast and Accurate Diagnostic Method for Ph-like ALL Using the Ncounter System

Kensuke Sasaki, MD, Kohta Miyawaki, MD PhD, Yuichiro Semba, MD PhD, Koji Kato, MD PhD, Jumpei Nogami, PhD, Takeshi Sugio, MD PhD, Toshihiro Miyamoto, MD PhD, Yoshikiyo Ito, MD PhD, Koji Nagafuji, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 375.

DOI: https://doi.org/10.1182/blood-2019-129625

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

DOI: https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Graft-Versus-Host Disease-Free, Relapse-Free Survival in Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma Provides a Novel Donor Selection Paradigm

Hiroyuki Muranushi, MD, Takero Shindo, MD PhD, Masakatsu Hishizawa, MD PhD, Masahito Tokunaga, MD PhD, Atsushi Wake, MD PhD, Nobuaki Nakano, MD, Tetsuya Eto, MD PhD, Michihiro Hidaka, MD PhD, Ilseung Choi, MD PhD, Toshihiro Miyamoto, MD PhD, Naoyuki Uchida, MD PhD, Yukiyoshi Moriuchi, MD, Yasuhiko Miyazaki, MD PhD, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, MD PhD, Koji Kato, MD PhD

Blood (2019) 134 (Supplement_1): 2008.

DOI: https://doi.org/10.1182/blood-2019-123318

Published: 2019

Journal Articles

Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)

Blood (2019) 134 (Supplement_1): 242.

DOI: https://doi.org/10.1182/blood-2019-128302

Published: 2019

Journal Articles

Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL

Kohta Miyawaki, MD PhD, Takuji Yamauchi, MD PhD, Takeshi Sugio, MD PhD, Kensuke Sasaki, MD, Hiroaki Miyoshi, MD PhD, Simon Osborne, PhD, Deborah Taylor, PhD, Koichi Ohshima, MD PhD, Koji Kato, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 396.

DOI: https://doi.org/10.1182/blood-2019-129613

Published: 2019

Journal Articles

Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial

Blood (2019) 134 (Supplement_1): 4103.

DOI: https://doi.org/10.1182/blood-2019-129107

Published: 2019

Journal Articles

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4032.

DOI: https://doi.org/10.1182/blood-2019-121723

Published: 2019

Journal Articles

Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel

Blood (2019) 134 (Supplement_1): 2883.

DOI: https://doi.org/10.1182/blood-2019-124492

Published: 2019

Journal Articles

Hematopoietic Stem Cell Transplantation in Children with Refractory Acute Lymphoblastic Leukemia

Yasuhiro Okamoto, MD, Yozo Nakazawa, MD, PhD, Masami Inoue, MD, Kenichiro Watanabe, MD PhD, Hiroaki Goto, MD, Nao Yoshida, MD PhD, Maiko Noguchi, MD, Atsushi Kikuta, MD, Koji Kato, MD PhD, Yoshiko Hashii, MD PhD, Yoshiko Atsuta, MD PhD, Motohiro Kato, MD PhD

Blood (2018) 132 (Supplement 1): 2173.

DOI: https://doi.org/10.1182/blood-2018-99-111301

Published: 2018

Journal Articles

Reduced-Intensity Allogeneic HSCT for Children and Adolescents/Young Adults with CML: A Study from the Adult and Pediatric CML Working Group of the Japan Society for Hematopoietic Cell Transplantation

Hiroyuki Shimada, MD PhD, Akihiko Tanizawa, MD PhD, Takeshi Kondo, MD PhD, Hideki Muramatsu, MD PhD, Masahiro Yasui, MD, Arinobu Tojo, MD PhD, Tokiko Nagamura-Inoue, MD PhD, Tetsuya Eto, MD PhD, Aiko Igarashi, MD, Heiwa Kanamori, MD PhD, Maho Sato, MD, Maiko Noguchi, MD, Tatsuo Ichinohe, MD PhD, Masami Inoue, MD, Koji Kato, MD PhD, Yoshiko Atsuta, MD PhD, Kazuteru Ohashi, MD PhD

Blood (2018) 132 (Supplement 1): 3008.

DOI: https://doi.org/10.1182/blood-2018-99-117836

Published: 2018

2 3 4 5

NARROW

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Indirectly Recognizable Epitopes Derived from Recipient Mismatched HLA-B Are Associated with Adverse Prognosis in Single-Unit Cord Blood Transplantation

Single-Cell Transcriptome Reveals Comprehensive Immune Profiles of T Follicular Helper Cell Lymphoma

YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

CHOP Plus Sequential Mogamulizumab As First-Line Therapy for Untreated Adult T-Cell Leukemia-Lymphoma

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia

A human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells

A Fast and Accurate Diagnostic Method for Ph-like ALL Using the Ncounter System

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Graft-Versus-Host Disease-Free, Relapse-Free Survival in Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma Provides a Novel Donor Selection Paradigm

Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)

Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL

Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel

Hematopoietic Stem Cell Transplantation in Children with Refractory Acute Lymphoblastic Leukemia

Reduced-Intensity Allogeneic HSCT for Children and Adolescents/Young Adults with CML: A Study from the Adult and Pediatric CML Working Group of the Japan Society for Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only